Stroke Recovery
Cerebrovascular event causing neurological deficit. MSC therapy reduces neuroinflammation, supports neuroregeneration, and promotes functional recovery.
Stroke — whether ischemic (clot-related) or hemorrhagic (bleeding) — causes sudden interruption of cerebral blood flow and rapid neuronal death in the affected territory. Survivors are frequently left with permanent motor deficits, speech impairment, cognitive changes, and reduced independence, even after intensive rehabilitation.
Standard acute stroke care (thrombolysis and thrombectomy) must be delivered within hours of onset and is unavailable or ineffective for many patients. Rehabilitation improves function within the first months but typically plateaus — leaving a large unmet need for subacute and chronic stroke patients.
MSC therapy is being evaluated as a neurorestorative intervention for patients in the subacute and chronic post-stroke window, where the goal shifts from reperfusion to neuroregeneration.
Intravenously administered MSCs cross into the ischemic penumbra and the peri-infarct zone, where they secrete VEGF, BDNF, and HGF — promoting angiogenesis, reducing neuroinflammation, and stimulating endogenous neural progenitor cells to differentiate and form new circuits. They also modulate the post-stroke immune cascade, which otherwise amplifies secondary neuronal injury.
Published clinical trials in subacute and chronic ischemic stroke patients — including randomized controlled studies — have demonstrated improvements in Barthel Index, Fugl-Meyer motor score, and National Institutes of Health Stroke Scale (NIHSS) in MSC-treated patients compared to controls.
Regen Cord's protocol targets the critical neuroinflammatory window. True Regen evaluates post-stroke patients — typically 1 week to 18 months after the event — for protocol eligibility, coordinating the full treatment timeline and post-treatment neurological follow-up.
- Improved motor function and strength in affected limbs
- Better performance on Barthel Index or Fugl-Meyer scale
- Improved speech and language function
- Reduced spasticity and dysphasia severity
- Enhanced neuroplasticity and rehab responsiveness
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.